News & Updates

For individuals who sustained herpes zoster infection, prior receipt of recombinant zoster vaccine appears to reduce the long-term risks of major adverse cardiovascular events, dementia, and death, according to a retrospective study.

Radiotherapy and imiquimod are both efficacious and well-tolerated in patients with complex lentigo maligna who are not suitable for surgery, with no negative effects on health-related quality of life (HRQoL) at 24 months, reports a study.

A recent study has shown the potential of the three-dimensional total body photography (3D TBP) in diagnosing general skin diseases, with high acceptance from both physicians and patients.

In patients with alopecia areata who received treatment with ritlecitinib, prior exposure to Janus kinase inhibitors is associated with reduced early response, reveals a study.

Among adults receiving adalimumab treatment, those with hidradenitis suppurativa appear to be at greater risk of infection than their psoriasis counterparts, as reported in a retrospective study.

New drug applications approved by US FDA as of 16-30 September 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Twice-daily application of ruxolitinib cream led to early and sustained improvement in the signs and symptoms of prurigo nodularis in adults, according to the pooled phase III TRuE-PN1 and TRuE-PN2 studies presented at EADV 2025.